Nanovibronix, Inc. (NASDAQ:FEED – Get Free Report) was the target of a significant growth in short interest in the month of July. As of July 15th, there was short interest totaling 161,665 shares, a growth of 165.7% from the June 30th total of 60,839 shares. Approximately 2.7% of the company’s stock are short sold. Based on an average daily volume of 507,400 shares, the days-to-cover ratio is currently 0.3 days.
Wall Street Analyst Weigh In
FEED has been the subject of several research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Nanovibronix in a research note on Tuesday, July 21st. Wall Street Zen upgraded Nanovibronix from a “strong sell” rating to a “sell” rating in a report on Sunday, July 12th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Nanovibronix has a consensus rating of “Sell”.
Read Our Latest Research Report on Nanovibronix
Insiders Place Their Bets
Nanovibronix Stock Performance
FEED stock traded down $0.02 during midday trading on Monday, reaching $0.36. 100,481 shares of the company’s stock traded hands, compared to its average volume of 5,933,434. The firm has a market capitalization of $2.18 million, a P/E ratio of -0.04 and a beta of 1.56. The firm has a fifty day simple moving average of $0.68. Nanovibronix has a 52 week low of $0.34 and a 52 week high of $17.40.
Nanovibronix (NASDAQ:FEED – Get Free Report) last released its quarterly earnings data on Monday, May 18th. The company reported ($6.88) earnings per share for the quarter. The business had revenue of $0.65 million during the quarter. Nanovibronix had a negative net margin of 923.20% and a negative return on equity of 54.25%.
About Nanovibronix
Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.
The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.
See Also
- Five stocks we like better than Nanovibronix
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Receive News & Ratings for Nanovibronix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanovibronix and related companies with MarketBeat.com's FREE daily email newsletter.
